Table 3. Comparison of characteristics after 6 months of biological disease-modifying antirheumatic drug (bDMARD) therapy between the patients with high and low anti-Porphyromonas gingivalis peptidylarginine deiminase (PPAD) immunoglobulin G (IgG) titers.
| Parameter | High titer group a (N = 30) | Low titer group a (N = 30) | P-value |
|---|---|---|---|
| Periodontal | |||
| Teeth present, no. (SD) | 24.6 (4.7) | 25.4 (3.5) | 0.52 |
| Plaque control record, mean (SD) % | 30.1 (17.8) | 30.3 (22.5) | 0.78 |
| Gingival index, mean (SD) | 0.8 (0.2) | 0.8 (0.2) | 0.46 |
| Bleeding on probing, mean (SD) % | 6.0 (7.4) | 4.2 (6.5) | 0.31 |
| Probing depth, mean (SD) mm | 2.5 (0.3) | 2.5 (0.3) | 0.88 |
| Clinical attachment level, mean (SD) mm | 2.7 (0.5) | 2.6 (0.4) | 0.83 |
| Rheumatologic | |||
| DAS28-CRP, mean (SD) | 2.5 (0.8) | 2.0 (0.6) | 0.005* |
| Tender joint count, mean (SD) | 1.8 (2.4) | 1.1 (1.1) | 0.82 |
| Swollen joint count, mean (SD) | 1.5 (2.0) | 1.2 (2.1) | 0.36 |
| VAS, mean (SD) mm | 19.1 (15.4) | 24.2 (36.9) | 0.85 |
| Anti-CCP IgG level, mean (SD) U/mL | 113.5 (162.9) | 105.2 (129.9) | 0.49 |
| RF level, mean (SD) IU/mL | 109.6 (199.7) | 66.2 (93.7) | 0.34 |
| CRP level, mean (SD) mg/dL | 0.4 (0.7) | 0.2 (0.4) | 0.39 |
SD: standard deviation; DAS28-CRP: disease activity score including 28 joints using C-reactive protein; VAS: visual analog scale; CCP: cyclic citrullinated peptide; RF: rheumatoid factor.
a Anti-PPAD IgG cut-off level, 0.822 ELISA unit.
* Significantly different between the groups (P < 0.05) (bold value).